Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic study of nadroparin anti-Xa activity in morbidly obese patients after bariatric surgery
2012-002816-19Phase 4Active
- Sponsor
- Rijnstate
- Start
- Jul 2012
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nadroparin in class III obesity and venous thromboembolism (VTE), sponsored by Rijnstate. Started Jul 2012; status: active.
02
Drugs
nadroparin
03
Conditions
class III obesityvenous thromboembolism (VTE)
Beyond the preview
Go deeper on 2012-002816-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002816-19.